EFTA02295528.pdf

"David Carter, Managing Director"

"Advisory Board Thomas Shenk, Ph.D. Dr. Shenk is the Elkins Professor"

"Advisory Board... Robert Dow, BSc MBChB FRCP (Edln)"

"Advisory Board Pamela R. Contag, Ph.D. Dr. Contag most recently served as Founder and CEO of Cobalt Technologies"

"Advisory Board... Howard Men Mr. Pien most recently served as Chairman of the Board and CEO of Medarex, Inc."

"DACART CAPITAL LLC $25M needed to reach $250M enterprise value in 5 years"

"Prediction BioSciences $9.3 M needed to reach $150 M enterprise value in 2 years... DACART CAPITAL LLC"

"OvationBio $25M needed to reach $200M enterprise value in 3 years DACART CAPITAL LLC"

"The Case for Investment. Investment opportunities identified. First 4 investments are teed up. Maji Therapeutics."

"DACART CAPITAL LLC San Francisco, California"

"OvationBio Investment Thesis... DACART CAPITAL LLC"

"ConcentRx Investment Thesis... DACART CAPITAL LLC"

"DACART CAPITAL LLC. DaCart Life Science"

"DACART CAPITAL LLC. DaCart Cleantech"

"David Carter, Managing Director... USA Life Science Fund #1"

"David Carter, Managing Director... European Life Science Fund #1"

"Only one FDA/EMA approved clot buster -tissue plasminogen activator (t-PA)"

"Only one FDA/EMA approved clot buster -tissue plasminogen activator (t-PA)"

"Michael Eisenson - Charlesbank, Managing Partner"

"Medarex, Inc. from 2007 to its acquisition by Bristol Myers Squibb Company in September 2009"

"References Michael Eisenson - Charlesbank, Managing Partner"

"Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University"

"Dr. Dow's current position is as Vice President of Strategic Product Development for PPD"

"Aug-06 Calper acq. $62 M"

"Nov-1 1 Perkin Elmer acq. $210 M"